PCT Rule 13 — Unity of Invention (MPEP Coverage Index) – BlueIron IP

PCT Rule 13 Unity of Invention

Source: Patent Cooperation Treaty (PCT)BlueIron Update:

This page consolidates MPEP guidance interpreting PCT Rule 13, including 74 rules from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only, it is not legal advice.

Summary

This section addresses the requirement to include indications of deposited biological material in international applications, as governed by PCT Rule 13 bis.3(a), and ensures that dependent claims must contain all features of their independent claim.

What this section covers

  • Practitioners must ensure that any indication of deposited biological material is included in the application as filed, subject to certain exceptions.
  • Dependent claims must contain all the features of their independent claim, regardless of whether the process for preparation is novel and inventive.

Key obligations

  • Drafters should ensure that all necessary indications of deposited biological material are included in the application as filed, to avoid objections under PCT Rule 13.
  • It is crucial for dependent claims to include all features of the independent claim, as failure to do so may lead to objections under PCT Rule 13.

Related Provisions

Based on MPEP Last Modified: 10/30/2024 08:50:22